{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Overall survival, defined as a patient being alive after transplant, is without regard to disease status.","groups":[{"description":"Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant","id":"OG000","title":"Haploidentical Transplant"}],"paramType":"NUMBER","populationDescription":"20 patients received haploidentical transplant and therefore were eligible to be evaluated for overall survival at 1 year","reportingStatus":"POSTED","timeFrame":"12 months","title":"Overall Survival at 12 Months","type":"SECONDARY","unitOfMeasure":"participants"}